

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P001	Copper chelation downregulates YTHDF2 RNA-binding protein causing growth inhibition and decreased MYCN expression	1. Genetic defects and dependencies in neuroblastoma	Jessica	Bell	Australia	Jessica Bell	Poster Session Group A + Rapid Fire Session 1A
P002	Non-canonical PRC1.1 targets BTG2 to maintain cyclin gene mRNAs and cell proliferation in neuroblastoma.	1. Genetic defects and dependencies in neuroblastoma	Shunpei	Satoh	Japan	Shunpei Satoh	Poster Session Group A
P003	m6A modification of TERRA RNA is required for telomere maintenance and is a therapeutic target for ALT positive Neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Roshan	Vaid	Sweden	Roshan Vaid	Poster Session Group A
P004	The novel long noncoding RNA linc53372 promotes neuroblastoma by inducing protein synthesis and AURKA and Myc over-expression	1. Genetic defects and dependencies in neuroblastoma	Tao	Liu	Australia	Tao Liu	Poster Session Group A
P005	Characterization of a novel 3D bone marrow metastatic neuroblastoma model	1. Genetic defects and dependencies in neuroblastoma	Diana	Corallo	Italy	Diana Corallo	Poster Session Group A
P006	TARGETING THE MAPK PATHWAY TO ALTER TRK RECEPTOR MEDIATED CELL FATE DECISIONS IN NEUROBLASTOMA	1. Genetic defects and dependencies in neuroblastoma	Stephanie	Maher	Ireland	Stephanie Maher	Poster Session Group A
P007	Targetable genetic alterations in high-risk NB patients. A SIOPEN study	1. Genetic defects and dependencies in neuroblastoma	Angela	Bellini	France	Angela Bellini	Poster Session Group A
P008	CLEAN - Cell Line ExplorAtion in Neuroblastoma: an interactive online tool for exploration of existing high throughput neuroblastoma studies	1. Genetic defects and dependencies in neuroblastoma	Jonatan	Gabre	Belgium	Jonatan Gabre	Poster Session Group A
P009	High-fat diet promotes metabolic alterations linked to inhibition of anaplastic lymphoma kinase.	1. Genetic defects and dependencies in neuroblastoma	Agata	Aniszewska	Sweden	Agata Aniszewska	Poster Session Group A
P010	E2F3 interactome profiling uncovers a new regulatory axis with MYCN to increase oncogenic reprogramming in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Giovanni	Perini	Italy	Giorgio Milazzo	Poster Session Group A
P011	Survivin over-expression is associated with a good prognosis in neuroblastoma patients	1. Genetic defects and dependencies in neuroblastoma	Fernanda	Pinhatti	Brazil	Fernanda Pinhatti	Poster Session Group A
P012	P300 interacted with N-Myc and regulated its protein stability via altering its posttranslational modifications in neuroblastoma.	1. Genetic defects and dependencies in neuroblastoma	Yeming	Wu	中国	Yeming Wu	Poster Session Group A
P013	Targeting m6A epitranscriptomic modification as a therapeutic strategy for MYCN amplified Neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Ketan	Thombare	Sweden	Ketan Thombare	Poster Session Group A
P014	Effect of Casiopeina-IIIa® on the expression of genes involved in intrinsic apoptosis of SK-N-SH neuroblastoma cells.	1. Genetic defects and dependencies in neuroblastoma	José Luis	Hernández Benítez	Mexico	José Luis Hernández Benítez	Poster Session Group A
P015	Identification and Validation of Tumor-Specific circRNAs as Biomarkers in Neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Leron	Kok	Netherlands	Leron Kok	Poster Session Group A
P017	β3-adrenergic receptor as prognostic marker of neuroblastoma relapse and malignancy	1. Genetic defects and dependencies in neuroblastoma	Marco	Tellini	Italy	Maura Calvani	Poster Session Group A
P018	The druggable target KAT2A forms a feedforward loop with MYCN to drive an oncogenic neuroblastoma transcriptional program	1. Genetic defects and dependencies in neuroblastoma	Zhihui	Liu	United States	Zhihui Liu	Poster Session Group A + Rapid Fire Session 1A
P019	High-resolution analysis of structural genomic alterations in neuroblastoma by linked-read whole-genome sequencing	1. Genetic defects and dependencies in neuroblastoma	Christoph	Bartenhagen	Germany	Christoph Bartenhagen	Poster Session Group A + Rapid Fire Session 1A
P020	Defining the landscape of circular RNAs in neuroblastoma unveils a global suppressive function of MYCN	1. Genetic defects and dependencies in neuroblastoma	Steffen	Fuchs	Germany	Steffen Fuchs	Poster Session Group A + Rapid Fire Session 1A
P021	The chromatin reader PHF6 interacts with RRM2 to control replication stress and DNA damage responses in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Lisa	Depestel	Belgium	Lisa Depestel	Poster Session Group A + Rapid Fire Session 1A
P022	Genetic predisposition to neuroblastoma results from a regulatory polymorphism promoting the adrenergic cell state in zebrafish and human.	1. Genetic defects and dependencies in neuroblastoma	Nina	Weichert-leahey	United States	Nina Weichert-leahey	Poster Session Group A + Rapid Fire Session 1A
P023	Designing Novel Drug Combinations to Improve Sensitivity of ALK-Driven Neuroblastoma Cells to Lorlatinib.	1. Genetic defects and dependencies in neuroblastoma	Smita	Matkar	United States	Smita Matkar	Poster Session Group A + Rapid Fire Session 1A
P024	Investigating the role of HMMR as a pro-oncogenic protein in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	andrew	stoker	United Kingdom	Andrew Stoker	Poster Session Group A
P025	Targeting cholesterol metabolism in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Han-fei	Ding	United States	Han-fei Ding	Poster Session Group A
P026	Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) regulates the cargo of extracellular vesicles and promotes neuroblastoma metastasis.	1. Genetic defects and dependencies in neuroblastoma	Mayura	Dhamdhere	United States	Mayura Dhamdhere	Poster Session Group A
P027	Inhibition of the RNA m6A Methyltransferase METTL3 Induces Neuroblastoma Differentiation and Impairs Tumor Growth	1. Genetic defects and dependencies in neuroblastoma	Monica	Pomaville	United States	Monica Pomaville	Poster Session Group A
P028	Activating ALK signaling stabilizes SLC3A2 protein for ALK-driven neuroblastoma tumorigenesis	1. Genetic defects and dependencies in neuroblastoma	Wei-Yun	Lai	Sweden	Wei-Yun Lai	Poster Session Group A

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P029	Drugging MYCN protein complexes in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Daniel	Fleischhauer	Germany	Daniel Fleischhauer	Poster Session Group A
P031	Treating the Untreatable by Disrupting the Antioxidant Response in Neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Judit	Liano Pons	Sweden	Judit Liano Pons	Poster Session Group A
P032	Germline variation affecting DNA repair genes correlates with chromosomal instability in Neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Giuseppe	D'alterio	Italy	Giuseppe D'alterio	Poster Session Group A
P033	CHD5 inhibits metastasis of neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Carmen	Dorneburg	Germany	Giovanna Stadler	Poster Session Group A
P034	Expression of the Notch ligand JAGGED1 in neuroblastoma is associated with a better prognosis	1. Genetic defects and dependencies in neuroblastoma	Carmen	Dorneburg	Germany	Carmen Dorneburg	Poster Session Group A
P035	Noncoding regulatory mutations as driving event for the oncogenic core regulatory circuitries of neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Vincenzo	Aievola	Italy	Vincenzo Aievola	Poster Session Group A
P036	MYCN cooperates with both WDR5 and G9a to orchestrate global gene transcription and govern a malignant phenotype of neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Zhihui	Liu	United States	Zhihui Liu	Poster Session Group A
P037	Genome analysis of 95 cases registered in JCCG-JNBSG JN-H-11 and JN-H-07 clinical studies for high-risk neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Miki	Ohira	Japan	Miki Ohira	Poster Session Group A
P038	Retrospective analysis of INRG clinical and genomic markers for 605 neuroblastomas in Japan: A report from JCCG-JNBSG	1. Genetic defects and dependencies in neuroblastoma	Miki	Ohira	Japan	Miki Ohira	Poster Session Group A
P039	Germline Genetic Contribution to Tumorigenesis and Progression in Neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Eun Seop	Seo	South Korea	Eun Seop Seo	Poster Session Group A
P040	DIFFERENTIAL IMPACTS OF ALK-WT, ALK-F1174L AND ALK-R1275Q ON NEUROBLASTOMA TUMOR HETEROGENEITY AND METASTATIC DISSEMINATION	1. Genetic defects and dependencies in neuroblastoma	Maya	El Natour	Switzerland	Maya El Natour	Poster Session Group A
P041	Mutations of 1p genes do not consistently abrogate tumor suppressor functions in 1p-intact neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Amos	Loh	Singapore	Amos Loh	Poster Session Group A
P042	DIAPH3 regulates proliferation and cytoskeletal modulation in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Ye	Yuan	Sweden	Ye Yuan	Poster Session Group A
P043	Identifying unique genomic gains associated with chromosome 17q gain translocation breakpoint in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Sinduja	Chandrasekaran	Germany	Sinduja Chandrasekaran	Poster Session Group A
P044	In vivo structure-function analysis supports a role for FANCI DNA helicase G4-unwinding activity in MYCN-driven neuroblastoma formation	1. Genetic defects and dependencies in neuroblastoma	Elien	Hilgert	Belgium	Elien Hilgert	Poster Session Group A
P045	SH-SY5Y cells overexpressing LIN28B gene release exosomal-microRNA that promote cell migration	1. Genetic defects and dependencies in neuroblastoma	Martina	Morini	Italy	Martina Morini	Poster Session Group A
P046	The prognostic impact of chromosome 11q loss in stage 4S neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Jessica	Theißen	Germany	Jessica Theißen	Poster Session Group A
P047	Circadian clock disruption in neuroblastoma, role of metabolic programming and effects on clinical outcomes	1. Genetic defects and dependencies in neuroblastoma	Tomas	Sjoeberg Bexelius	Sweden	Tomas Sjoeberg Bexelius	Poster Session Group A
P048	Conditional knock-out of the TERT gene in neuroblastoma cell lines	1. Genetic defects and dependencies in neuroblastoma	Julia	Riedel	Germany	Julia Riedel	Poster Session Group A
P049	Intercellular extrachromosomal DNA copy number heterogeneity drives cancer cell state diversity	1. Genetic defects and dependencies in neuroblastoma	Maja-Celine	Stöber	Germany	Maja-Celine Stöber	Poster Session Group A
P050	MYCN mRNA is a post-transcriptional regulator of RNA transcripts via microRNAs in High-Risk Neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Soledad	Gómez-González	Spain	Soledad Gómez-González	Poster Session Group A
P051	LSD1/CoREST complexes contribute to neuroblastoma aggressiveness by modulating core regulatory TFs' transcriptional programs	1. Genetic defects and dependencies in neuroblastoma	Giorgio	Milazzo	Italy	Giorgio Milazzo	Poster Session Group A
P052	Aryl Hydrocarbon Receptor (AhR) is a Tumor Promoter in MYCN-Amplified Neuroblastoma Via Suppression of Differentiation	1. Genetic defects and dependencies in neuroblastoma	Kanita	Chaudhry	United States	Kanita Chaudhry	Poster Session Group A
P053	Inhibition of TENEURIN-4 promotes differentiation and suppresses neuroblastoma growth	1. Genetic defects and dependencies in neuroblastoma	Sara	Abu Ajamieh	Sweden	Sara Abu Ajamieh	Poster Session Group A
P054	Can overexpression of genes located on chromosome 17q in Schwann cell precursors cause neuroblastoma?	1. Genetic defects and dependencies in neuroblastoma	Kristina	Ihrmark Lundberg	Sweden	Kristina Ihrmark Lundberg	Poster Session Group A
P055	Comparison of telomere maintenance and gene expression-based classification for risk assessment of neuroblastoma patients	1. Genetic defects and dependencies in neuroblastoma	Carolina	Rosswog	Germany	Carolina Rosswog	Poster Session Group A

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P056	Assessment of telomere maintenance mechanisms in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Carolina	Rosswog	Germany	Carolina Rosswog	Poster Session Group A
P057	Genomic ALK alterations in primary and relapsed neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Carolina	Rosswog	Germany	Carolina Rosswog	Poster Session Group A
P058	Inhibition of OCT4 binding at the MYCN locus induces neuroblastoma cell death accompanied by alteration of protein-coding potential of RNAs	1. Genetic defects and dependencies in neuroblastoma	Kazuma	Nakatani	Japan	Kazuma Nakatani	Poster Session Group A
P059	The adrenergic-specific lncRNA NESPR regulates PHOX2B expression and neuroblastoma cell viability	1. Genetic defects and dependencies in neuroblastoma	Louis	Delhaye	België	Louis Delhaye	Poster Session Group A
P060	Discovering vulnerabilities of MYCN-independent neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Polina	Perepelkina	Austria	Polina Perepelkina	Poster Session Group A
P061	Oncogene amplification identifies a subgroup of intermediate-risk neuroblastoma patients with inferior outcome: A SIOPEX study	1. Genetic defects and dependencies in neuroblastoma	Fang Chyi	Fong	United Kingdom	(Hon) Fang Chyi Fong	Poster Session Group A
P062	Identifying a Synthetic Lethal Signature for MYCN-Amplified Neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Matthew	Nagy	United States	Matthew Nagy	Poster Session Group A
P063	Telomere maintenance mechanisms are associated with inferior survival and segmental chromosomal abnormalities in an intermediate-risk neuroblastoma subgroup: A SIOPEX study	1. Genetic defects and dependencies in neuroblastoma	Hannah	Hartley	United Kingdom	Louise K. Stephenson	Poster Session Group A
P064	TERC AND MYNN VARIANTS ASSOCIATED WITH MYCN NON-AMPLIFIED NEUROBLASTOMA : A PRELIMINARY STUDY.	1. Genetic defects and dependencies in neuroblastoma	Thamiris	Gimenez	Brazil	Thamiris Gimenez	Poster Session Group A
P065	Haddad Syndrome and Neuroblastoma: a case report	1. Genetic defects and dependencies in neuroblastoma	Federica	Carra	Italy	Federica Carra	Poster Session Group A
P066	Altered arginine metabolism is an exploitable vulnerability in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Kimberley	Hanssen	Australia	Kimberley Hanssen	Poster Session Group A
P068	Integrative network analysis characterizes regulatory programs for dosage sensitive genes in high-risk neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Vanessa	Vermeirssen	Belgium	Vanessa Vermeirssen	Poster Session Group A
P069	Actionable mechanisms and biomarkers to predict selective Bcl2-family inhibitor responses in neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Michael	Hogarty	United States	Douglas Saforo	Poster Session Group A
P070	Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance	4. Plasticity in neuroblastoma and normal development	Adriana	Mañas	Sweden	Adriana Mañas	Poster Session Group A + Rapid Fire Session 1A
P072	High Content imaging screen identifies lysosomal activity and MAPK signaling as specific vulnerabilities of mesenchymal neuroblastomas	4. Plasticity in neuroblastoma and normal development	Sonja	Herter	Germany	Sonja Herter	Poster Session Group A
P074	Study of spatial and temporal epigenetic heterogeneity in high-risk neuroblastoma suggests role of H3K27me3-mediated repression	4. Plasticity in neuroblastoma and normal development	Charlotte	Butterworth	France	Charlotte Butterworth	Poster Session Group A + Rapid Fire Session 1A
P075	Palbociclib releases the latent differentiation capacity of neuroblastoma cells	4. Plasticity in neuroblastoma and normal development	Kirsty	Ferguson	United Kingdom	Kirsty Ferguson	Poster Session Group A + Rapid Fire Session 1A
P076	Atypical neuroblastoma: screening of urinary catecholamine excretion and mIBG avidity at diagnosis, a retrospective study.	4. Plasticity in neuroblastoma and normal development	Anna	BOROVKOV	France	Anna BOROVKOV	Poster Session Group A + Rapid Fire Session 1B
P077	Cause and consequence of intra- and inter-tumor heterogeneity in zebrafish models of neuroblastoma.	4. Plasticity in neuroblastoma and normal development	Nora	Fresmann	Germany	Nora Fresmann	Poster Session Group A + Rapid Fire Session 1B
P078	Hypoxia Promotes a Transition from Adrenergic to Mesenchymal Cell State in Neuroblastoma	4. Plasticity in neuroblastoma and normal development	Gepoliano	Chaves	United States	Mark Applebaum	Poster Session Group A
P079	Adaptive phenotypic cell plasticity is a cancer evolutionary driver in paediatric solid cancers: "plasticity-first" evolvability	4. Plasticity in neuroblastoma and normal development	Alejandra	Bruna	United Kingdom	Alejandra Bruna	Poster Session Group A
P080	Cellular and molecular mechanisms involved in neuroblastoma plasticity	4. Plasticity in neuroblastoma and normal development	Margot	Gautier	France	Margot Gautier	Poster Session Group A
P081	Targeting lineage heterogeneity via cGAS-STING	4. Plasticity in neuroblastoma and normal development	Adam	Wolpaw	United States	Adam Wolpaw	Poster Session Group A
P082	Uncovering Initiation Mechanisms of Neuroblastoma via Transcriptional Profiling of Neural Crest Development	4. Plasticity in neuroblastoma and normal development	Jenny	Hsin	United States	Jenny Hsin	Poster Session Group A
P083	The DDR2 (Discoid Domain Receptor 2) defines SCP/bridge subpopulations and is a novel therapeutic target in Neuroblastoma	4. Plasticity in neuroblastoma and normal development	Jason	Shohet	United States	Jason Shohet	Poster Session Group A
P084	Micro-environmental regulation of cancer cell fate plasticity	4. Plasticity in neuroblastoma and normal development	Stina	Andersson	Sweden	Stina Andersson	Poster Session Group A
P085	Deciphering the transcriptomic landscape of a neuroblastoma transgenic mouse model	4. Plasticity in neuroblastoma and normal development	Bethel Tesfai	Embaie	Sweden	Bethel Tesfai Embaie	Poster Session Group A

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P087	Characterization of neural crest stem-like cells and their contribution to aggressiveness	4. Plasticity in neuroblastoma and normal development	Aida	Amador-Álvarez	Spain	Aida Amador-Álvarez	Poster Session Group A
P088	DISSECTING THE ROLE OF AUTOPHAGY IN METASTATIC NEUROBLASTOMA	4. Plasticity in neuroblastoma and normal development	Silvia	Lampis	Italy	Silvia Lampis	Poster Session Group A
P089	Modelling neuroblastoma using human induced pluripotent stem cells	4. Plasticity in neuroblastoma and normal development	Giuseppe	Santopolo	Sweden	Giuseppe Santopolo	Poster Session Group A
P090	Targeted DamID identifies novel transcriptional targets of Alk signalling in Drosophila neuroendocrine cells.	4. Plasticity in neuroblastoma and normal development	Sanjay Kumar	Sukumar	Sweden	Sanjay Kumar Sukumar	Poster Session Group A
P094	Single-cell Multi-omics Identifies Dynamic Cancer Cell State Reprogramming and Immune Environment Dysfunction in Human Metastatic Neuroblastoma	4. Plasticity in neuroblastoma and normal development	Natalie	Wu	United States	Natalie Wu	Poster Session Group A
P095	Cohesin-mediated 3D genome structure defines Neuroblastoma cell subtypes and their plasticity.	4. Plasticity in neuroblastoma and normal development	Jeeyoun	Kang	United States	Jeeyoun Kang	Poster Session Group A
P096	Adrenal medulla development markers as a tool for improved patient risk stratification: elucidation of the neuroblastoma clinical heterogeneity	4. Plasticity in neuroblastoma and normal development	Lukas	Sourada	Czech Republic	Lukas Sourada	Poster Session Group A
P097	Subtyping and diagnostic classification of neuroblastic tumours using multi-scale transcriptomics	4. Plasticity in neuroblastoma and normal development	Sarah	Cohen-gogo	Canada	Sarah Cohen-gogo	Poster Session Group A
P098	Tumor-associated macrophages and mesenchymal stromal cells modulate adrenergic to mesenchymal state transition in neuroblastoma	4. Plasticity in neuroblastoma and normal development	Meng-hua	Lee	United States	Meng-hua Lee	Poster Session Group A
P099	Single-cell multiomic investigation of chromosomal alterations in normal adrenal development, neuroblastoma, and pheochromocytoma	4. Plasticity in neuroblastoma and normal development	Cedar	Schloo	Germany	Cedar Schloo	Poster Session Group A
P100	The Role of ASCL1 and Its Interactors in Neuroblastoma	4. Plasticity in neuroblastoma and normal development	Lidiya	Mykhaylechko	United Kingdom	Lidiya Mykhaylechko	Poster Session Group A
P101	Chromaffin-to-neuroblast cell state transitions drive tumor plasticity in NF1 and KIF1Bb deficient neuroblastoma, pheochromocytoma and composite tumors.	4. Plasticity in neuroblastoma and normal development	Susanne	Schlisio	Sweden	Susanne Schlisio	Poster Session Group A
P102	A key role for HIF2α in determining differentiation potential and a noradrenergic cellular state in neuroblastoma	4. Plasticity in neuroblastoma and normal development	Juan	Yuan	Sweden	Juan Yuan	Poster Session Group A
P103	Chromaffin-to-neuroblast cell state transitions drive tumor plasticity in NF1 and KIF1Bb deficient neuroblastoma, pheochromocytoma and composite tumors	4. Plasticity in neuroblastoma and normal development	Peng	Cui	Sweden	Peng Cui	Poster Session Group A
P104	NTRK1/TrkA-induced nuclear reorganisation and abrogation of checkpoint responses are critical determinants of differentiation and proliferation in neuroblastoma cells	4. Plasticity in neuroblastoma and normal development	Alexander	Schramm	Germany	Alexander Schramm	Poster Session Group A
P105	Hypoxia induces expression of periostin and chemotherapy-specific resistance in SH-SY-5Y cells.	4. Plasticity in neuroblastoma and normal development	Kyriaki	Karapiperi	United Kingdom	Kyriaki Karapiperi	Poster Session Group A
P106	Optimization of Bulk RNA-seq Deconvolution of Serial Samples from Patients with High Risk Neuroblastoma (HR-NBL) Using Single Cell RNA-seq (scRNAseq)	4. Plasticity in neuroblastoma and normal development	Steven	Pastor	United States	Steven Pastor	Poster Session Group A
P107	Syngeneic TH-MYCN tumors convert to a mesenchymal phenotype, lose GD2, and increase inflammatory signaling: implications for preclinical immunotherapy	4. Plasticity in neuroblastoma and normal development	Piotr	Jung	United States	Piotr Jung	Poster Session Group A
P108	Exploring neuroblast-chromaffin state transitions in human neuroblastoma and paraganglioma	4. Plasticity in neuroblastoma and normal development	Jiacheng	Zhu	Sweden	Maria Arceo	Poster Session Group A
P109	Transcriptional-noise-driven phenotypic plasticity as a source of non-genetic evolution in neuroblastoma	4. Plasticity in neuroblastoma and normal development	Alejandro	Allo Anido	United Kingdom	Alejandro Allo Anido	Poster Session Group A
P110	A single-cell meta-analysis on gene regulatory programs and signaling in neuroblastoma	4. Plasticity in neuroblastoma and normal development	Vittorio	Zanzani	Belgium	Vittorio Zanzani	Poster Session Group A
P112	Growth inhibition of neuroblastoma cells by anti-NLRR1 monoclonal antibodies	2. Precision therapy	Atsushi	Takatori	Japan	Atsushi Takatori	Poster Session group B
P113	Evaluating the RIST molecular-targeted regimen in a neuroblastoma spheroid cell culture model	2. Precision therapy	Carina	Kaess	Germany	Carina Kaess	Poster Session group B

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P114	Evaluating the RIST molecular-targeted regimen in an in vitro cell culture model of Ewing sarcoma	2. Precision therapy	Emre	Yildirim	Germany	Emre Yildirim	Poster Session group B
P115	Identification of TIMP-3 as a metastatic regulator of neuroblastoma	2. Precision therapy	Pei-Yi	Wu	Taiwan	Pei-Yi Wu	Poster Session group B
P116	The multikinase inhibitor Sitravatinb blocks neuroblastoma tumorigenesis in vitro and in vivo.	2. Precision therapy	Jason	Shohet	United States	Jason Shohet	Poster Session group B
P117	Unraveling the polypharmacology of beta-blockers in neuroblastoma using chemoproteomics	2. Precision therapy	Baptiste	Mouysset	France	Baptiste Mouysset	Poster Session group B
P119	Investigating Molecular Glues as a New Therapeutic Approach for High-Risk Neuroblastoma	2. Precision therapy	Ian	Delahunty	United States	Ian Delahunty	Poster Session group B
P120	Fenretinide-loaded mesenchymal stromal cell-derived extracellular vesicles as novel drug against human neuroblastoma	2. Precision therapy	Alessia	Zorzoli	Italy	Alessia Zorzoli	Poster Session group B
P121	NANOSENSE: a Trojan horse reconditioning high-risk neuroblastoma to a ferroptosis sensitive state	2. Precision therapy	Ine	Koeken	Belgium	Ine Koeken	Poster Session group B
P122	Casiopeina-IIIia® treatment inhibits the migration of xenografted neuroblastoma cells in zebrafish (Danio rerio).	2. Precision therapy	Carmen	Mejía	Mexico	Carmen Mejía	Poster Session group B
P123	Evaluation of the activity of the mPTP components in neuroblastoma cells treated with Casiopeina-IIIia®.	2. Precision therapy	Mónica	Martínez-Pacheco	Mexico	Mónica Martínez-Pacheco	Poster Session group B
P125	Drug repurposing for high-risk neuroblastoma	2. Precision therapy	Katarzyna	Radke	Sweden	Katarzyna Radke	Poster Session Group B + Rapid Fire Session 1B
P126	CDK12 as a target for combinatorial drugging of high-risk neuroblastoma	2. Precision therapy	Joshua Robert	Goulding	United Kingdom	Joshua Robert Goulding	Poster Session Group B + Rapid Fire Session 1B
P127	Exploring the role of MYCN in the mitochondria to discover MYCN-Amplified tumour vulnerabilities	2. Precision therapy	Soraya	Epp	Ireland	Student Soraya Epp	Poster Session Group B + Rapid Fire Session 1B
P128	Unbiased high-throughput screening and preclinical testing in PDX models identifies synergistic combinations with the BCL2 inhibitor venetoclax	2. Precision therapy	Jamie	Fletcher	Australia	Jamie Fletcher	Poster Session Group B + Rapid Fire Session 2A
P129	Pseudometastatic allografting of TH-MYCN neuroblastoma cells with loss of p53 function provides an efficient syngeneic model of advanced-stage, high-risk disease	2. Precision therapy	Garrett	Brodeur	United States	Ferro Nguyen	Poster Session Group B + Rapid Fire Session 2A
P130	A zebrafish larvae xenograft model for high-throughput drug testing and precision medicine in neuroblastoma	2. Precision therapy	Joshua Robert	Goulding	United Kingdom	Joshua Robert Goulding	Poster Session Group B + Rapid Fire Session 2A
P131	Joint inhibition of oncogenic and epigenetic targets PPM1D and KDM6B synergistically suppresses neuroblastoma growth	2. Precision therapy	Diana	Treis	Sweden	Diana Treis	Poster Session Group B + Rapid Fire Session 1B
P132	Splicing dependency of neuroblastoma	2. Precision therapy	JUN	YANG	United States	JUN YANG	Poster Session group B
P133	Neuroblastoma resistant to lorlatinib upregulates FGFR2 and acquires sensitivity to FGFR inhibition	2. Precision therapy	Perla	Pucci	United Kingdom	Perla Pucci	Poster Session group B
P134	Ketogenic diet and metformin enhance the effect of cyclophosphamide on neuroblastoma	2. Precision therapy	Barbara	Kofler	Austria	Barbara Kofler	Poster Session group B
P135	PREME: AN ITALIAN PERSONALIZED MEDICINE PROGRAM FOR HIGH-RISK NEUROBLASTOMA	2. Precision therapy	Fabio	Pastorino	Italy	Mario Capasso	Poster Session group B
P136	SHP2 and ALK inhibitor combinations are synergistic in ALK-driven neuroblastoma models	2. Precision therapy	Ivette	Valencia-Sama	Canada	Ivette Valencia-Sama	Poster Session group B
P137	Large scale drug response comparison across different neuroblastoma cell model systems	2. Precision therapy	Kasper	Karlsson	Sweden	Kasper Karlsson	Poster Session group B
P138	Screening of NB PDTc models with a large compound drug library. A COMPASS study.	2. Precision therapy	Angela	Bellini	France	Angela Bellini	Poster Session group B
P139	Quasomes are novel platform to deliver RNA-based therapies for Neuroblastoma	2. Precision therapy	Ariadna	Boloix	Spain	Ariadna Boloix	Poster Session group B
P140	Targeting SWI/SNF ATPase SMARCA4 in core transcription factors-addicted neuroblastoma suppresses cell plasticity and invasiveness	2. Precision therapy	Zhihui	Liu	United States	Zhihui Liu	Poster Session group B
P141	Novel combination therapy for MYCN-driven neuroblastoma targeting the deubiquitinase USP5	2. Precision therapy	Belamy	Cheung	Australia	Belamy Cheung	Poster Session group B
P142	Fast, in vivo drug-response evaluation with single cell resolution of human-zebrafish xenografts (Zefix)	2. Precision therapy	Anja IH	Hagemann	Germany	Anja IH Hagemann	Poster Session group B
P143	Dual AURKA (LY3295668) and BCL2 (venetoclax) inhibition is potently effective in preclinical models of neuroblastoma (NB)	2. Precision therapy	David	Groff	United States	David Groff	Poster Session group B

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P144	In vitro drug screens as a mirror of in vivo drug sensitivity, a next step in neuroblastoma precision medicine	2. Precision therapy	Marlinde	Schoonbeek	Netherlands	Marlinde Schoonbeek	Poster Session group B
P145	The EZH2 inhibitor PF-06821497 Demonstrates High Specificity and Potency Against ALT Neuroblastoma	2. Precision therapy	Alexander	Daniels	United States	Alexander Daniels	Poster Session group B
P146	Refractory Adult-Onset Neuroblastoma with STRN-NTRK2 Fusion Treated with Larotrectinib and Dinutuximab	2. Precision therapy	Michael	Mitchell	United States	Michael Mitchell	Poster Session group B
P147	The ultrahigh-risk subgroup in neuroblastoma cases identified through DNA methylation analysis and its treatment which exploit cancer metabolism	2. Precision therapy	Kentaro	Watanabe	Japan	Kentaro Watanabe	Poster Session group B
P149	Degradation of XIAP as a novel targeting strategy for high-risk neuroblastoma	2. Precision therapy	Amos	Loh	Singapore	Zhi Xiong Chen	Poster Session group B
P150	Personalized therapy of patients with neuroblastoma: the experience of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology	2. Precision therapy	Natalya	Andreeva	Russian Federation	Natalya Andreeva	Poster Session group B
P151	Standardization and validation of procedures for detection of the ALK genetic status in neuroblastoma samples by SIOPEN Biology reference laboratories	2. Precision therapy	Alexandra	Saint-Charles	France	Alexandra Saint-Charles	Poster Session group B
P152	Preclinical PK/PD in Neuroblastoma of the MYCN-inhibitor BGA002 and modelling of dose prediction for clinical phase 1	2. Precision therapy	Roberto	Tonelli	Italy	Roberto Tonelli	Poster Session group B
P153	Exploring the combinatorial potential of the ROCK2-specific inhibitor KDO25 for neuroblastoma therapy	2. Precision therapy	Conny	Tümmeler	Sweden	Conny Tümmeler	Poster Session group B
P154	Adrenergic and mesenchymal signatures are identifiable in neuroblastoma cell free DNA and correlate with metastatic disease burden	2. Precision therapy	Omar	Vayani	United States	Mark Applebaum	Poster Session group B
P155	Amplicon structure creates collateral therapeutic vulnerabilities in neuroblastoma	2. Precision therapy	Yi	Bei	Germany	Yi Bei	Poster Session group B
P156	Treatment Strategies for Incidentally Found Neuroblastoma in Children younger than 18 Months Old: The Roles of 18F-FDOPA and 18F-FDG PET	2. Precision therapy	Wan-ting	Hung	Taiwan	Wan-ting Hung	Poster Session group B
P157	Purine metabolism: a metabolic weakness of neuroblastoma and synergistic effects with APR-246.	2. Precision therapy	Vid	Mlakar	Switzerland	Vid Mlakar	Poster Session group B
P158	Targeting PI3K and CDK4/6, or PARP and WEE1 in neuroblastoma cell lines	2. Precision therapy	Monika	Lukoseviciute	Sweden	Monika Lukoseviciute	Poster Session group B
P159	Exploring Dinutuximab Beta as a potential theragnostic vector for non-invasive molecular imaging and targeted radiotherapy of high-risk neuroblastoma	2. Precision therapy	Peter	Gawne	United Kingdom	Peter Gawne	Poster Session group B
P160	Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation	2. Precision therapy	Jill	Deleu	Belgium	Jill Deleu	Poster Session group B
P161	Evaluating the efficacy of Enhancer of Zeste Homolog 2 inhibitors in combination with anti-GD2/isotretinoin for the treatment of high-risk neuroblastoma	2. Precision therapy	Jinhui	Gao	United Kingdom	Jinhui Gao	Poster Session group B
P162	BCLAF1 Functionalization Against Relapsed/Refractory Neuroblastoma	2. Precision therapy	Erika	D'agostino	Italy	Erika D'agostino	Poster Session group B
P163	Combined inhibition of EZH2 and EGFR results in neuroblastoma cell death	2. Precision therapy	Jara	Martín Serrano	Spain	Jara Martín Serrano	Poster Session group B
P164	Molecular and clinical impact of PTPN11/SHP2 in neuroblastoma	2. Precision therapy	Caroline	Nunes-Xavier	Spain	Caroline Nunes-Xavier	Poster Session group B
P165	Targeted AURKA degradation: towards new therapeutic agents for neuroblastoma	2. Precision therapy	Muhammad	Rishfi	Belgium	Simon Krols	Poster Session group B
P166	Dual inhibition of ALK and SHP2 synergistically suppresses neuroblastoma cell proliferation	2. Precision therapy	Ezgi	Uçkun	Sweden	Ezgi Uçkun	Poster Session group B
P167	ALK signaling primes the DNA damage response allowing exploitation of ATR inhibition in ALK-driven neuroblastoma.	2. Precision therapy	Marcus	Borenäs	Sweden	Marcus Borenäs	Poster Session group B
P168	DEVELOPMENT OF A SWI/SNF INHIBITION STRATEGY FOR THE TREATMENT OF HIGH-RISK NEUROBLASTOMA	2. Precision therapy	Adrià	Molero Valenzuela	Spain	Adrià Molero Valenzuela	Poster Session group B
P169	MYCN-amplified neuroblastomas are highly and selectively sensitive to inhibition of N-myristoyltransferases.	2. Precision therapy	James	Zhang	United Kingdom	James Zhang	Poster Session group B

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P170	Regulation of oncogenic MYCN transcription and tumor growth in neuroblastoma by the CDK9 inhibitor KB-0742	2. Precision therapy	Evon	Poon	United Kingdom	Evon Poon	Poster Session group B
P171	Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification	2. Precision therapy	Xiaoxiao	Hu	China	Xiaoxiao Hu	Poster Session group B
P172	Translational precision medicine in childhood cancer – a representative NBL case	2. Precision therapy	Reidun	Aesoey	Norway	Reidun Aesoey	Poster Session group B
P173	131-I-MIBG therapy in combination with PARP inhibitors for relapsed neuroblastoma with DNA repair pathway alterations	2. Precision therapy	Sarah	Cohen-gogo	Canada	Sarah Cohen-Gogo	Poster Session group B
P174	RUVBL1 and RUVBL2 are prognostic biomarkers and putative therapeutic targets for high-risk neuroblastoma.	2. Precision therapy	Joachim	Siaw	Belgium	Joachim Siaw	Poster Session group B
P175	The two-drug regimen panobinostat/lorlatinib is effective against neuroblastomas driven by genomic TERT rearrangements and ALK mutations	2. Precision therapy	Rasmus	Linke	Germany	Rasmus Linke	Poster Session group B
P176	Targeting the extracellular matrix in therapy-resistant pediatric tumors	2. Precision therapy	Marta	Emperador	Germany	Marta Emperador	Poster Session group B
P177	Successful targeting of ALK in relapsed or refractory metastatic neuroblastoma with lorlatinib monotherapy	2. Precision therapy	Torben	Ek	Sweden	Torben Ek	Poster Session group B
P178	Dual ROCK inhibitor RKI-1447 promotes cell death and emerges as a synergistic partner for BET inhibitors in neuroblastoma	2. Precision therapy	Adena	Pepich	Sweden	Adena Pepich	Poster Session group B
P179	Design of Retinoid-Responsive Suicide Gene Systems For Neuroblastoma Treatment	2. Precision therapy	Enzo	Giardina	United Kingdom	Enzo Giardina	Poster Session group B
P180	Targeting of the polyamine transporter ATP13A3 sensitises neuroblastoma cells to DFMO	2. Precision therapy	Weiman	Gao	Australia	Mujahid Azfar	Poster Session group B
P181	Preclinical evaluation of the MDM2/p53 binding antagonist idasanutlin and PARP inhibitor olaparib alone and in a novel combination in neuroblastoma	2. Precision therapy	Hannah	Hartley	United Kingdom	Hannah Hartley	Poster Session group B
P182	LAROTRECTINIB AS SOLE ALTERNATIVE TREATMENT FOR NEUROBLASTOMA PRESENTING NTRK3-SCAPER GENE FUSION	2. Precision therapy	Nathalia	Halley	Brazil	Nathalia Halley	Poster Session group B
P183	Utilization of Liquid Biopsy To Identify Genomic Alterations for Pediatric High-Risk Neuroblastoma	2. Precision therapy	Maribel	Martinez	United States	Maribel Martinez	Poster Session group B
P184	In vivo identification of active drugs and drug combinations for high-risk neuroblastoma using zebrafish models	2. Precision therapy	Shuning	He	United States	Shuning He	Poster Session group B
P185	TP53-dependent synergism of BET and IDH2 inhibitors in MYCN/cMYC-driven Neuroblastomas	2. Precision therapy	Nuria	Martínez Alarcón	Spain	Nuria Martínez Alarcón	Poster Session group B
P186	Molecular-Guided Therapy for the Treatment of Relapsed/Refractory Neuroblastoma: Results from the Beat Childhood Cancer Research Consortium Trial MGT009	2. Precision therapy	Jacqueline	Kraveka	United States	Jacqueline Kraveka	Poster Session group B
P187	Identification of drug resistance mechanisms by single cell imaging of neuroblastoma reporter cells.	2. Precision therapy	Timofey	Lebedev	Russian Federation	Timofey Lebedev	Poster Session group B
P188	Usefulness of WB MRI with diffusion-weighted sequences for neuroblastoma characterization, monitoring in combination with precision medicine programs: a case report.	2. Precision therapy	Federica	Carra	Italy	Annalisa Tondo	Poster Session group B
P190	The splicing inhibitor isoginkgetin sensitizes MYCN-amplified neuroblastoma cells to vincristine	2. Precision therapy	Melinda	Halasz	Ireland	Melinda Halasz	Poster Session group B
P191	Targeting TERT activation in high risk neuroblastoma	2. Precision therapy	Chandrika	Behura	United States	Chandrika Behura	Poster Session group B
P192	Mutational topography reflects clinical neuroblastoma heterogeneity	3. Genetic defects driving resistance and relapse	Elias	Rodriguez-fos	Germany	Elias Rodriguez-fos	Poster Session Group C
P193	Comprehensive allelic series of ATRX In-Frame-Fusions in neuroblastoma reveals neomorphic protein functions	3. Genetic defects driving resistance and relapse	Sina	Jostes	United States	Sina Jostes	Poster Session Group C + Rapid Fire Session 2B
P194	The C57 BL/6 Th-ALKF1174L/MYCN genetically-engineered murine model of high-risk neuroblastoma enables the preclinical study of metastatic drug resistant relapse.	3. Genetic defects driving resistance and relapse	Lizzie	Tucker	United Kingdom	Lizzie Tucker	Poster Session Group C + Rapid Fire Session 2B
P195	Nucleosome footprinting enables inference of expression profiles in circulating tumor DNA from neuroblastoma patients	3. Genetic defects driving resistance and relapse	Yasmine	Iddir	France	Yasmine Iddir	Poster Session Group C + Rapid Fire Session 2B
P196	Detection of epigenetic cell states in cell-free DNA of high-risk neuroblastoma patients	3. Genetic defects driving resistance and relapse	Lotte	Cornelli	Belgium	Lotte Cornelli	Poster Session Group C + Rapid Fire Session 2B

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P197	Adrenergic-lineage genes are epigenetically repressed in immature MES-type neuroblastoma cells	3. Genetic defects driving resistance and relapse	Imene	Jridi	Netherlands	Imene Jridi	Poster Session Group C
P198	Sequential cfDNA studies by ddPCR and WES enable early detection of relapse and clonal evolution during ALK-inhibitor treatment in neuroblastoma	3. Genetic defects driving resistance and relapse	Charles	Bobin	France	Charles Bobin	Poster Session Group C
P199	YAP1-TEAD2 mediates therapy resistance in RAS-driven neuroblastoma	3. Genetic defects driving resistance and relapse	Jenny	Shim	United States	Jenny Shim	Poster Session Group C
P200	Characterizing Chemoimmunotherapy Response in Patients with ALK-mutated Relapsed or Refractory Neuroblastoma	3. Genetic defects driving resistance and relapse	Rachel	Prorok	United States	Rachel Prorok	Poster Session Group C
P201	EXTRACELLULAR VESICLES FROM DRUG-RESISTANT NEUROBLASTOMA CELLS REGULATE THE METABOLISM OF NONCANCEROUS CELLS THROUGH THE TRANSFER OF GLYCOLYTIC ENZYMES	3. Genetic defects driving resistance and relapse	Olga	Piskareva	Ireland	Olga Piskareva	Poster Session Group C
P202	MOLECULAR MECHANISMS OF CHEMORESISTANCE IN NEUROBLASTOMA PATIENTS	3. Genetic defects driving resistance and relapse	Marta	Garcia Lopez	Spain	Marta Garcia Lopez	Poster Session Group C
P203	Chemotherapy response of neuroblastoma patient-derived xenografts correlated with patient outcome and identified gene expression patterns associated with drug resistance	3. Genetic defects driving resistance and relapse	Min	Kang	United States	Min Kang	Poster Session Group C
P204	The impact of MYCN depletion on neuroblastoma cell survival and immune evasion	3. Genetic defects driving resistance and relapse	Kyabeth	Torres-Rodriguez	United States	Kyabeth Torres-Rodriguez	Poster Session Group C
P205	The impact of MYCN on therapy-induced senescence in neuroblastoma	3. Genetic defects driving resistance and relapse	Giulia	Montuori	Germany	Giulia Montuori	Poster Session Group C
P206	Pharmacogenetics of treatment response and toxicity in French patients with metastatic High-Risk Neuroblastoma	3. Genetic defects driving resistance and relapse	Anne Sophie	Defachelles	France	Gudrun Schleiermacher	Poster Session Group C
P208	IgA3.0 ch14.18 antibodies are effective in preclinical neuroblastoma models without inducing neuropathic pain	5. Immune therapy	Marjolein	Stip	Nederland	Marjolein Stip	Poster Session Group C + Rapid Fire Session 2A
P209	Best of two worlds: Engineering NKT-cells to generate an alternative adaptive cell therapy strategy against neuroblastoma	5. Immune therapy	Annelisa	Cornel	Netherlands	Annelisa Cornel	Poster Session Group C + Rapid Fire Session 2A
P210	GPC2-directed CAR T cells are safe and efficacious in preclinical models of neuroblastoma	5. Immune therapy	Kristopher	Bosse	United States	Kristopher Bosse	Poster Session Group C + Rapid Fire Session 2A
P211	Immunomodulatory effect of the MEK pathway inhibitor enhanced the efficacy of GD2-CAR-T cell therapy against neuroblastoma	5. Immune therapy	Akimasa	Tomida	Japan	Akimasa Tomida	Poster Session Group C + Rapid Fire Session 2A
P212	Antigen-driven cytokine expression systems to enhance the function and overcome challenges of CAR T cell therapy in neuroblastoma	5. Immune therapy	Reona	Okada	United States	Reona Okada	Poster Session Group C + Rapid Fire Session 2A
P213	Desensitizing the Autonomic Nervous System to mitigate anti-GD2 Monoclonal Antibody Side Effects.	5. Immune therapy	Jaume	Mora	Spain	Jaume Mora	Poster Session Group C + Rapid Fire Session 2A
P215	Peptide-centric CAR T cell therapy targeting the tumor-associated antigen PRAME	5. Immune therapy	Erin	Runbeck	United States	Erin Runbeck	Poster Session Group C + Rapid Fire Session 2A
P216	Novel immune interventions for neuroblastoma from simultaneous single-cell RNA and T cell receptor sequencing of tumors	5. Immune therapy	Elisa	Zappa	Netherlands	Elisa Zappa	Poster Session Group C
P217	T-cell inflammation is prognostic of survival in high-risk, MYCN-non-amplified neuroblastoma	5. Immune therapy	Maria	Kaufman	United States	Mark Applebaum	Poster Session Group C
P218	The immunocytokine FAP-IL-2v enhances anti-neuroblastoma efficacy of the anti-GD2 antibody dinutuximab beta	5. Immune therapy	Nikolai	Siebert	Germany	Nikolai Siebert	Poster Session Group C
P219	Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma	5. Immune therapy	Aleksandra	Wieczorek	Poland	Aleksandra Wieczorek	Poster Session Group C
P220	Antitumor Activity of the Investigational B7-H3 Antibody-drug Conjugate, Vobramitamab Duocarmazine, in Preclinical Neuroblastoma Models	5. Immune therapy	Mirco	Ponzoni	Italy	Enzo Calarco	Poster Session Group C
P221	Naxitamab combined with granulocyte-macrophage colony-stimulating factor as end-induction consolidation for high-risk neuroblastoma patients in first complete remission.	5. Immune therapy	Jaume	Mora	Spain	Jaume Mora	Poster Session Group C
P222	Chemotherapy used in induction for high-risk neuroblastoma improves efficacy of anti-GD2 therapy with dinutuximab beta in preclinical spheroid models.	5. Immune therapy	Sascha	Troschke-Meurer	Germany	Sascha Troschke-Meurer	Poster Session Group C
P223	Pilot clinical trial of DNA vaccination against neuroblastoma	5. Immune therapy	Inna	Praliskouskaya	Belarus	Inna Praliskouskaya	Poster Session Group C

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P224	Adverse Reaction (AR) Reporting in Naxitamab Chinese Early Access (EA) Treatment Administered by Children's Hospital of Fudan University	5. Immune therapy	Anna	Murzhenko	United States	Josefine Askholm	Poster Session Group C
P225	Effect of Prior Anti-GD2 Immunotherapy on Efficacy and Safety for Patients Treated with Naxitamab in Trial 201	5. Immune therapy	Anna	Murzhenko	United States	Jaume Mora	Poster Session Group C
P226	Chemotherapy resistant neuroblastoma cells with stem-like properties are characterized by increased GD2 surface abundance	5. Immune therapy	Lena	Meissner	Germany	Lena Meissner	Poster Session Group C
P227	Long term follow-up of treatment with anti-GD2 antibody (ch14.18/SP2/0) in children with metastatic high-risk neuroblastoma: Long-term toxicity and quality-of-life	5. Immune therapy	Tim	Flaadt	Germany	Tim Flaadt	Poster Session Group C
P228	Safety and efficacy of naxitamab plus modified GM-CSF dosing in treating primary refractory or high-risk neuroblastoma in first complete remission	5. Immune therapy	Brian	Kushner	United States	Brian Kushner	Poster Session Group C
P229	Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy	5. Immune therapy	Brian	Kushner	United States	Brian Kushner	Poster Session Group C
P230	High-dose naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in first complete remission: A phase II trial	5. Immune therapy	Brian	Kushner	United States	Brian Kushner	Poster Session Group C
P231	Apoptosis-Promoting Drugs in Combination with Chimeric Antigen Receptor Cell Therapies to Treat High-Risk Neuroblastoma	5. Immune therapy	Mariam	Hakoum	Canada	Mariam Hakoum	Poster Session Group C
P232	Photoimmunotherapy using anti-GD2 antibody for neuroblastoma	5. Immune therapy	JIMEI	ZHAO	Japan	JIMEI ZHAO	Poster Session Group C
P234	Defining the mechanisms of B7-H3 overexpression and role in neuroblastoma metastasis and immune evasion	5. Immune therapy	Catherine	Wingrove	United States	Catherine Wingrove	Poster Session Group C
P235	Dual GD2 and PTK7 targeted $\gamma\delta$ T cell immunotherapy for neuroblastoma	5. Immune therapy	Hunter	Jonus	United States	Hunter Jonus	Poster Session Group C
P236	Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma	5. Immune therapy	Dai	Chung	United States	Jingbo Qiao	Poster Session Group C
P237	Case report: Successful therapy of multiply relapsed neuroblastoma patient with poor organ function with escalating doses of ANBL1221	5. Immune therapy	Brittany	Frazer	United States	Brittany Frazer	Poster Session Group C
P238	THE IDENTIFICATION OF GAMMA DELTA T CELLS AS CELLS WITH IMMUNOTHERAPY POTENTIAL IN HUMAN NEUROBLASTOMA	5. Immune therapy	Bronte Manouk	Verhoeven	Sweden	Bronte Manouk Verhoeven	Poster Session Group C
P239	Anti-tumor reactivity of $\alpha\beta$ T cells engineered to express a $\gamma\delta$ 2TCR (TEG A3) towards solid tumor in vitro models	5. Immune therapy	Ronja	Pscheid	Netherlands	Ronja Pscheid	Poster Session Group C
P240	SHED L1CAM IMPAIRS CAR T CELL EFFICACY AGAINST NEUROBLASTOMA	5. Immune therapy	Lena	Andersch	Germany	Lena Andersch	Poster Session Group C
P241	Functional characterization of CAR-T cells derived from different sources for the treatment of Neuroblastoma	5. Immune therapy	Lorena	García	Spain	Lorena García	Poster Session Group C
P242	Induction of telomere dysfunction as a therapeutic strategy to target neuroblastoma by immune checkpoint inhibition	5. Immune therapy	Stefanie	Höppner	Germany	Stefanie Höppner	Poster Session Group C
P243	Organoid-specific optimization of killing assays to test novel immunotherapies in a high-throughput system	5. Immune therapy	Femke	Van Den Ham	Netherlands	Femke Van Den Ham	Poster Session Group C
P244	B7-H3 immune checkpoint protein in neuroblastoma therapy response	5. Immune therapy	Maite	Emaldi	Spain	Maite Emaldi	Poster Session Group C
P245	End of Induction Response and Toxicities in Children with High-Risk Neuroblastoma Treated with Dinutuximab Chemoimmunotherapy in all Cycles of Induction	5. Immune therapy	Margaret	Cupit-Link	United States	Margaret Cupit-Link	Poster Session Group C
P246	Tumor irradiation and anti-GD2 immunocytokine (hu14.18-IL2) drive curative responses to CAIR therapy in a murine model of high-risk, treatment-resistant neuroblastoma	5. Immune therapy	Paul	Sondel	United States	Paul Sondel	Poster Session Group C
P247	Induced innate CD8+T cells engineered to express a new class of anti-GD2 chimeric antigen receptors for neuroblastoma immunotherapy	5. Immune therapy	Björn	Lode	Germany	Björn Lode	Poster Session Group C
P249	Preclinical evaluation of O-acetylated GD2-specific CAR $\gamma\delta$ 2T cells targeting neuroblastoma cells	5. Immune therapy	STEPHANE	BIRKLE	France	Hortense Alliot	Poster Session Group C
P250	Ex-vivo activation and expansion of NK cells to generate "memory-like" NK cells for the treatment of relapsed or refractory neuroblastoma	5. Immune therapy	Ken	DeSantes	United States	Ken DeSantes	Poster Session Group C
P251	Pharmacologically inhibiting MYCN improves L1CAM-directed CAR T cell efficacy against MYCN-amplified Neuroblastoma	5. Immune therapy	Laura	Grunewald	Germany	Laura Grunewald	Poster Session Group C

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P252	Secondary hematologic malignancies after treatment including compartmental antibody-based radioimmunotherapy for solid tumors with CNS metastases	5. Immune therapy	Alexandre	Troullioud Lucas	United States	Alexandre Troullioud Lucas	Poster Session Group C
P253	The Yes-Associated Protein (YAP) regulates GD2 immunotherapy response in high-risk neuroblastoma	5. Immune therapy	Adeiye	Pilgrim	United States	Kelly Goldsmith	Poster Session Group C
P254	Combined chemotherapy and immune checkpoint blockade treatment enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma	5. Immune therapy	Valeria	Lucarini	Italy	Doriana Fruci	Poster Session Group C
P255	CHRNA3 as a super-enhancer-driven oncoprotein and potential immunotherapeutic target in high-risk neuroblastoma	5. Immune therapy	Patrick	Schuerch	United States	Patrick Schuerch	Poster Session Group C
P256	Neuroblastoma Cells Modulate Macrophage Differentiation and Polarization in 3D Co-Culture Models	5. Immune therapy	Esther	Coronado	Spain	Esther Coronado	Poster Session Group C
P257	Preliminary real-world data study of Dinutuximab β in the treatment of Chinese children with high-risk or recurrent/ refractory neuroblastoma	5. Immune therapy	Xiaojun	Yuan	China	Xiaojun Yuan	Poster Session Group C
P258	Butyrophilin 3A2 plays a critical role in phosphoantigen-mediated gamma delta ($\gamma\delta$) T cell cytotoxicity of neuroblastoma	5. Immune therapy	Andrew	Ho	United States	Hunter Jonus	Poster Session Group C
P259	Omalizumab for management of urticaria in patients receiving anti-GD2 immunotherapy.	5. Immune therapy	Angela	Lentini-Rivera	United States	Angela Lentini-Rivera	Poster Session Group C
P260	Neuroblastoma extracellular vesicles expose GPC2 and activate GPC2 CAR T cells in an antigen-dependent manner	5. Immune therapy	Anna Maria	Giudice	United States	Anna Maria Giudice	Poster Session Group C
P261	Controlled RRM2 protein degradation for pharmacological target validation and functional analysis in MYCN-driven neuroblastoma	1. Genetic defects and dependencies in neuroblastoma	Soetkin	Leys	Belgium	Soetkin Leys	Poster Session Group C
P263	The role of immunosuppressive tumor-associated macrophages in Mycn-driven neuroblastoma	5. Immune therapy	Hiroyuki	Yoda	United States	Hiroyuki Yoda	Poster Session Group C
P264	Repression of the STING pathway by MYCN contributes to the cold immunophenotype of MYCN amplified neuroblastoma	5. Immune therapy	Stefano	Di Giulio	Italy	Stefano Di Giulio	Poster Session Group C
P265	In-depth phenotypic and functional characterization of Natural Killer Cells in Bone Marrow of High-Risk neuroblastoma patients	5. Immune therapy	Chiara	Vitale	Italy	Chiara Vitale	Poster Session Group C
P266	"Exploring the Potential of Non-Canonical ORFs as Immunotherapeutic Targets in Neuroblastoma"	5. Immune therapy	Damon	Hofman	Netherlands	Damon Hofman	Poster Session Group C
P267	A Phase I Study of Expanded Autologous Natural Killer Cells with Dinutuximab for Relapsed/Refractory Neuroblastoma: A NANT Consortium Study.	5. Immune therapy	Araz	Marachelian	United States	Araz Marachelian	Poster Session Group C
P268	Targeting PHOX2B with CAR T cells: Progress from peptide discovery to clinical trial	5. Immune therapy	Mark	Yarmarkovich	United States	Mark Yarmarkovich	Poster Session Group C
P269	Characterizing the effects of polyamine synthesis inhibition and TGF β inhibition on the neuroblastoma immune microenvironment	5. Immune therapy	Christina	Turn	United States	Christina Turn	Poster Session Group C
P270	Development of murine Gpc2 CAR T cells and syngeneic preclinical models to identify mechanisms of immunotherapeutic resistance in neuroblastoma	5. Immune therapy	Anna Maria	Giudice	United States	Anna Maria Giudice	Poster Session Group C
P271	Persistence of Racial and Ethnic Disparities in Risk and Survival for Patients with Neuroblastoma: An International Neuroblastoma Risk Group Project	6. Clinical trials and relapse treatment	Mohansrinivas	Chennakesavalu	United States	Mohansrinivas Chennakesavalu	Poster Session Group D + rapid Fire Session 1B
P272	Modeling strategies for survival in Neuroblastoma: focus on long-term survival prediction in stage 4 patients >1 year treated within SIOPEN-HR-NBL1.	6. Clinical trials and relapse treatment	Ulrike	Poetschger	Österreich	Ulrike Poetschger	Poster Session Group D + rapid Fire Session 1B
P274	GANGLIONEUROMAS IN CHILDHOOD: A SINGLE-CENTER EXPERIENCE WITH 70 CASES	6. Clinical trials and relapse treatment	Bilgehan	Yalcin	Turkey	Bilgehan Yalcin	Poster Session Group D
P275	Second Malignant Neoplasms in Neuroblastoma Patients: clinical data of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology	6. Clinical trials and relapse treatment	Dinara	Utalieva	Russian Federation	Dinara Utalieva	Poster Session Group D
P276	Clinicopathological Implications of Ganglioneuroblastoma Intermixed Detected at Diagnosis	6. Clinical trials and relapse treatment	Shakeel	Modak	United States	Shakeel Modak	Poster Session Group D
P277	Successful endoscopic approach for peripheral neuroblastic tumor -Single center experience-	6. Clinical trials and relapse treatment	Naonori	Kawakubo	Japan	Naonori Kawakubo	Poster Session Group D

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P279	Localised unresectable Neuroblastoma: a report of the Italian neuroblastoma registry	6. Clinical trials and relapse treatment	Martina	Fragola	Italy	Stefania Sorrentino	Poster Session Group D
P280	Altered gut Microbiome composition in infants and children with Neuroblastoma	6. Clinical trials and relapse treatment	Maria Valeria	Corrias	Italy	Maria Valeria Corrias	Poster Session Group D
P281	The extent of resection does not alter the outcome in patients with Ganglioneuroma and Ganglioneuroblastoma Intermixed.	6. Clinical trials and relapse treatment	Sajid	Qureshi	India	Sajid Qureshi	Poster Session Group D
P282	Associations of gut microbiota and GD2/GD3 vaccine response in pediatric patients with high-risk neuroblastoma	6. Clinical trials and relapse treatment	Oriana	Miltiadous	United States	Oriana Miltiadous	Poster Session Group D
P284	RATIONAL FOR IRRADIATION OF PERSISTING OLIGO-SKELETAL METASTASES TO IMPROVE SURVIVAL OF METASTATIC NEUROBLASTOMA PATIENTS WITH A POOR RESPONSE TO CHEMOTHERAPY?	6. Clinical trials and relapse treatment	Lea	Rossillon	France	Pablo Berlanga	Poster Session Group D
P285	Low-Dose Intravenous Ketamine for Primary Pain Control During Naxitamab and Dinutuximab Anti-GD2 Immunotherapy Treatment	6. Clinical trials and relapse treatment	Rosanna	Silber	United States	Rosanna Silber	Poster Session Group D
P286	Focal nodular hyperplasia in children after treatment of neuroblastoma: A report of 84 cases	6. Clinical trials and relapse treatment	Verena	Paulsen	Germany	Verena Paulsen	Poster Session Group D
P287	Pulmonary complications in paediatric high risk neuroblastoma: A single centre experience	6. Clinical trials and relapse treatment	Shampavi	Sri Haran	Australia	Shampavi Sri Haran	Poster Session Group D
P288	Long-term results of combined polychemotherapy, MIBG131 in vivo purging, ABMT and allogeneic dendritic cell vaccine (DCVs) for high-risk neuroblastomas (HRNBs)	6. Clinical trials and relapse treatment	Nathalia	Halley	Brazil	Nathalia Halley	Poster Session Group D
P289	131I-MIBG Therapy for Patients with Neuroblastoma in Singapore	6. Clinical trials and relapse treatment	Shui Yen	Soh	Singapore	Shui Yen Soh	Poster Session Group D
P290	Interim analysis of the UK relapsed high risk neuroblastoma study	6. Clinical trials and relapse treatment	Nermine	Basta	United Kingdom	Nermine Basta	Poster Session Group D
P292	Neuroblastoma Disease Response Tool: Implementation of a longitudinal disease assessment tool in neuroblastoma to calculate response.	6. Clinical trials and relapse treatment	Jennifer	Sims	United States	Meaghan Granger	Poster Session Group D
P293	Incidence of Adrenal Insufficiency in Children with Neuroblastoma During and/or Shortly After Therapy	6. Clinical trials and relapse treatment	Keri	Streby	United States	Keri Streby	Poster Session Group D
P294	Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease	6. Clinical trials and relapse treatment	Shakeel	Modak	United States	Shakeel Modak	Poster Session Group D
P295	INCIDENCE, SEVERITY, AND DURATION OF SINUSOIDAL OBSTRUCTION SYNDROME IN HIGH-RISK NEUROBLASTOMA: CONTRIBUTORS, MANAGEMENT, AND OUTCOMES IN A MODERN MULTI-INSTITUTIONAL COHORT	6. Clinical trials and relapse treatment	John	Lucas	United States	John Lucas	Poster Session Group D
P296	Long-term Follow-up of the Children's Oncology Group (COG) Intermediate-risk Phase III ANBL0531 Study Using Response- and Biology-Based Therapy	6. Clinical trials and relapse treatment	Erin	Barr	United States	Erin Barr	Poster Session Group D + rapid Fire Session 1B
P297	Predictors of Differential Outcomes According to Response to Induction Chemotherapy in High-Risk Neuroblastoma	6. Clinical trials and relapse treatment	Elizabeth	Sokol	United States	Elizabeth Sokol	Poster Session Group D + rapid Fire Session 1B
P298	Response-Adapted Consolidation Therapy Strategy for Patients With Metastatic High-Risk Neuroblastoma: Results From the SMC NB-2014 Study	6. Clinical trials and relapse treatment	Eun Seop	Seo	South Korea	Eun Seop Seo	Poster Session Group D + rapid Fire Session 1B
P299	Surgical Outcome of A Nationwide Phase II Study of Delayed Local Treatment for Children with High-risk Neuroblastoma (JN-H-11)	6. Clinical trials and relapse treatment	Akihiro	Yoneda	Japan	Akihiro Yoneda	Poster Session Group D + rapid Fire Session 2B
P300	Late disappearance of minimal residual disease after KIR-ligand mismatched allogeneic CBT suggests KIR mismatched NK cell activity to Neuroblastoma	6. Clinical trials and relapse treatment	Rowaida	Alahmadi	Japan	Rowaida Alahmadi	Poster Session Group D + rapid Fire Session 2B
P301	Naxitamab-Based Chemoimmunotherapy for Resistant High-Risk Neuroblastoma: Results of "HITS" Phase II Study (NCT03189706)	6. Clinical trials and relapse treatment	Shakeel	Modak	United States	Shakeel Modak	Poster Session Group D
P302	ALK inhibitors for therapy of adult-onset neuroblastoma	6. Clinical trials and relapse treatment	Shakeel	Modak	United States	Shakeel Modak	Poster Session Group D
P303	A Randomised Phase II Trial of Radiotherapy Dose Escalation, Facilitated by Intensity Modulated Arc Radiotherapy Techniques, in High-Risk Neuroblastoma	6. Clinical trials and relapse treatment	Mark	Gaze	United Kingdom	Mark Gaze	Poster Session Group D
P304	Alpha-1 adrenergic antagonists sensitize neuroblastoma to differentiation by isotretinoin	6. Clinical trials and relapse treatment	Francesca	Broso	Italy	Francesca Broso	Poster Session Group D

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P305	Single-agent activity of the anti-GD2 antibody dinutuximab beta given as long-term continuous infusion in relapsed and refractory neuroblastoma (APN311-304).	6. Clinical trials and relapse treatment	Holger	Lode	Deutschland	Holger Lode	Poster Session Group D
P306	Sustained complete response of neuroblastoma with metronomic chemotherapy: A Case Series	6. Clinical trials and relapse treatment	Jinhua	Zhang	China	Jinhua Zhang	Poster Session Group D
P307	BEACON2: a SIOPEN-ITCC platform multi-arm multi-stage trial for relapsed neuroblastoma.	6. Clinical trials and relapse treatment	Lucas	Moreno	Spain	Lucas Moreno	Poster Session Group D
P308	Toxicity of Anti-GD2 Antibody Immunotherapy after KIR Ligand-mismatched Allogeneic Stem Cell Transplantation in Patients with High-risk Neuroblastoma	6. Clinical trials and relapse treatment	Nobuhiro	Nishio	Japan	Nobuhiro Nishio	Poster Session Group D
P309	Real-world outcomes of High-risk Neuroblastoma from a tertiary care centre in India	6. Clinical trials and relapse treatment	Venkata Rama Mohan	Gollamudi	India	Venkata Rama Mohan Gollamudi	Poster Session Group D
P310	Mixed response after radiopharmaceutical therapy with 177Lu-DOTATATE in a refractory high-risk neuroblastoma patient – early results from the LuDO-N Trial	6. Clinical trials and relapse treatment	Sammy Se Whee	Park	Sweden	Sammy Se Whee Park	Poster Session Group D
P311	A postinduction Curie Score of more than 2 in MYCN-nonamplified tumor treated by JN-H-15 was not associated with poor prognosis	6. Clinical trials and relapse treatment	Kimikazu	Matsumoto	Japan	Kimikazu Matsumoto	Poster Session Group D
P312	KIR ligand-incompatible allogeneic cord blood transplantation for relapsed stage 4 neuroblastoma in a multicenter trial	6. Clinical trials and relapse treatment	Shinsuke	Kataoka	Japan	Shinsuke Kataoka	Poster Session Group D
P313	Development of combinations of ABTL0812 to inform the first in child phase I trial in children with relapsed/refractory neuroblastoma	6. Clinical trials and relapse treatment	Maria J	Perez	Spain	Maria J Perez	Poster Session Group D
P314	Poor radiotherapy worsens overall survival for patients with high-risk neuroblastoma: report from the SIOPEN High-Risk Neuroblastoma Study 1 radiotherapy committee.	6. Clinical trials and relapse treatment	Sarah	Kelly	Belgium	Sarah Kelly	Poster Session Group D
P315	Characterizing Response to Repeated Episodes of Chemoimmunotherapy in Patients with Relapsed and Refractory Neuroblastoma	6. Clinical trials and relapse treatment	SaraJane	Onyeama	United States	SaraJane Onyeama	Poster Session Group D
P316	Differentiation of residual neuroblastoma manifestations in patients with neuroblastoma Stage 4S	6. Clinical trials and relapse treatment	Barbara	Hero	Germany	Barbara Hero	Poster Session Group D
P317	EVALUATION OF PALBOCICLIB IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY NEUROBLASTOMA	6. Clinical trials and relapse treatment	Theodore W.	Laetsch	United States	Margaret E. Macy	Poster Session Group D
P318	Combination of Carboplatin and Etoposide in Patients with Relapsed or Pro-gressing Neuroblastoma	6. Clinical trials and relapse treatment	Sarina Kim	Butzer	Germany	Sarina Kim Butzer	Poster Session Group D
P319	Matched External Control Analysis of Survival in High-Risk Neuroblastoma (HRNB) Patients Receiving DFMO Maintenance: MYCN Status Impact	6. Clinical trials and relapse treatment	Giselle	Saulnier Sholler	United States	Giselle Saulnier Sholler	Poster Session Group D
P320	Sensitivity Analyses of Event Free and Overall Survival in High-Risk Neuroblastoma Patients Receiving DFMO Maintenance with Matched External Controls	6. Clinical trials and relapse treatment	Giselle	Saulnier Sholler	United States	Giselle Saulnier Sholler	Poster Session Group D
P321	Tolerability and Safety of Eflornithine (DFMO) in High-Risk Neuroblastoma (HRNB) Patients Treated with DFMO Maintenance Therapy	6. Clinical trials and relapse treatment	Jacqueline	Kraveka	United States	Jacqueline Kraveka	Poster Session Group D
P322	Canadian Relapse/Refractory High-Risk Neuroblastoma (CANOE) Registry	6. Clinical trials and relapse treatment	Pauline	Tibout	Canada	Pauline Tibout	Poster Session Group D
P323	Oral Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated, relapsed metastatic neuroblastoma: a single center case series	6. Clinical trials and relapse treatment	Maria Antonietta	De Ioris	Italy	Maria Antonietta De Ioris	Poster Session Group D
P324	Individualized treatment plans for patients with the Recurrent/Refractory Neuroblastoma (R/R NB): experience from the Children Hospital, Anna Meyer, Florence (Italy).	6. Clinical trials and relapse treatment	Federica	Carra	Italy	Federica Carra	Poster Session Group D
P325	INCIDENCE AND 5-YEAR SURVIVAL OF PEDIATRIC NEUROBLASTOMA IN THE UNITED STATES	6. Clinical trials and relapse treatment	Kevin	Campbell	United States	Kevin Campbell	Poster Session Group D
P326	Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA	7. Novel diagnostics and imaging	Jill	Deleu	Belgium	Jill Deleu	Poster Session Group D + Rapid Fire Session 2B

ANR2023 POSTER PRESENTATIONS



Schedule poster presentations

Poster session A (P1 – P110) – Monday 15th May, 16:20 – 17:30 hrs.
 Poster session B (P111 – P191) – Tuesday 16th May, 11:45 – 13:45 & 16:50 – 17:30 hrs.
 Poster session C (P192 – P270) – Wednesday 17th May, 12:40 – 13:40 hrs.
 Poster session D (P271 – P350) – Thursday 18th May, 12:10 – 13:10 hrs.

Schedule Rapid fire sessions

Rapid Fire session 1A - Monday 15th May, 11:35 -11:50 hrs.
 Rapid Fire session 1B - Tuesday 16th May, 11:30 -11:45 hrs.
 Rapid Fire session 2A - Wednesday 17th May, 12:25 -12:40 hrs.
 Rapid Fire session 2B - Thursday 18th May, 12:05 -12:20 hrs.

Paper Reference	Paper Title	Theme	Submitted by:			Presenting Author	Session
			First Name	Last Name	Country		
P327	Interference in the Measurement of Metanephrines by Over acidification of Urine samples of Neuroblastoma patients	7. Novel diagnostics and imaging	Ronit	Tamir	Israel	Ronit Tamir	Poster Session Group D
P328	The prognostic value of detecting isolated neuroblastoma cells in bone marrow by immunocytochemistry	7. Novel diagnostics and imaging	Juliette	Assy	France	Gudrun Schleiermacher	Poster Session Group D
P329	Optimization of neuroblastoma xenograft models for the analysis of tumoral cell-free RNA in murine blood plasma	7. Novel diagnostics and imaging	Hanne	Van Droogenbroeck	Belgium	Hanne Van Droogenbroeck	Poster Session Group D
P330	Multiplexing of genomic targets for high-risk neuroblastoma MRD diagnostics using mediator probe PCR chemistry	7. Novel diagnostics and imaging	Anna	Schröer	Germany	Anna Schröer	Poster Session Group D + Rapid Fire Session 2B
P331	Longitudinal cell-free DNA analysis in patients with high-risk neuroblastoma is suitable for early relapse and actionable target detection	7. Novel diagnostics and imaging	Marco	Lodrini	Germany	Marco Lodrini	Poster Session Group D + Rapid Fire Session 2B
P332	5-hydroxymethylcytosine in cell-free DNA as a potential biomarker of therapy response in a phase 3 high-risk neuroblastoma clinical trial	7. Novel diagnostics and imaging	Mark	Applebaum	United States	Mark Applebaum	Poster Session Group D
P333	LC-MS/MS detection of circulating GD2 ganglioside in plasma samples from neuroblastoma patients and age-matched healthy children. Diagnostic and prognostic evaluation.	7. Novel diagnostics and imaging	Maria Valeria	Corrias	Italy	Martina Morini	Poster Session Group D
P334	Preliminary digital study of vitronectin and cilengitide related to neuroblast behavior in silk fibroin 3D hydrogel cultures	7. Novel diagnostics and imaging	Isaac	Vieco-Martí	Spain	Isaac Vieco-Martí	Poster Session Group D
P335	Biotensegral studies in neuroblastoma 3D in vitro models reveal potential therapeutic improvements	7. Novel diagnostics and imaging	Isaac	Vieco-Martí	Spain	Isaac Vieco-Martí	Poster Session Group D
P336	Cancer stem cell evaluation on 3D in vitro models has translational impact for neuroblastoma risk classification	7. Novel diagnostics and imaging	Isaac	Vieco-Martí	Spain	Isaac Vieco-Martí	Poster Session Group D
P337	Clinical Implications of Residual Lesions Assessed Using Multiple Modalities Following High-Dose Chemotherapy as a Prognostic Factor in High-Risk Neuroblastoma Patients	7. Novel diagnostics and imaging	Kyung-Nam	Koh	대한민국	Kyung-Nam Koh	Poster Session Group D
P338	Cell-free RNA from plasma in patients with neuroblastoma: exploring the technical and clinical potential	7. Novel diagnostics and imaging	Nathalie	Lak	Netherlands	Nathalie Lak	Poster Session Group D
P339	Mapping distinct tumor subpopulations in human neuroblastoma using scRNA-seq and novel spatial omics	7. Novel diagnostics and imaging	Ioanna	Tsea	Sweden	Ioanna Tsea	Poster Session Group D
P340	Liquid Biopsy Identifies Divergent Epigenomic Pathways with Actionable Targets in High-Risk Neuroblastomas	7. Novel diagnostics and imaging	Eva M	Trinidad	Spain	Eva M Trinidad	Poster Session Group D
P341	Mechanotransduction-related genes are dysregulated in high-risk neuroblastomas	7. Novel diagnostics and imaging	Rosa	Noguera	Spain	Rosa Noguera	Poster Session Group D
P342	Plasma 3-O-methyl-dopa: a promising biomarker that can be measured from dried plasma microsamples using liquid chromatography-tandem mass spectrometry	7. Novel diagnostics and imaging	Giuliana	Cangemi	Italy	Martina Morini	Poster Session Group D
P343	Prospective multicenter observational study of minimal residual disease detected by 7NB-mRNAs ddPCR assay in high-risk neuroblastoma patients	7. Novel diagnostics and imaging	Noriyuki	Nishimura	Japan	Noriyuki Nishimura	Poster Session Group D
P344	COMBINED BLOOD AND BONE MARROW CELL FREE DNA AND DISSEMINATED TUMOR CELL ANALYSIS FOR DISEASE MONITORING AND EARLY RELAPSE DETECTION	7. Novel diagnostics and imaging	Marie	Bernkopf	Austria	Marie Bernkopf	Poster Session Group D
P345	DETECTION OF MINIMAL RESIDUAL DISEASE (MRD) IN HIGH RISK NEUROBLASTOMA IS ASSOCIATED WITH SURVIVAL OUTCOMES	7. Novel diagnostics and imaging	Nina	Gelineau	Netherlands	Nina Gelineau	Poster Session Group D
P346	Revival of the catecholamines	7. Novel diagnostics and imaging	Yvette	Matser	Netherlands	Yvette Matser	Poster Session Group D
P347	Bone marrow involvement in patients with high-risk neuroblastoma: a comparison between RTqPCR and [123I]mIBG imaging	7. Novel diagnostics and imaging	Atia	Samim	Nederland	Atia Samim	Poster Session Group D
P348	Wait and see strategy in an adolescent case of bilateral adrenal neuroblastoma.	7. Novel diagnostics and imaging	Federica	Carra	Italy	Annalisa Tondo	Poster Session Group D
P349	Plasma cell-free DNA analysis uncovered tumor heterogeneity and clonal evolution during treatment for relapsed neuroblastoma	7. Novel diagnostics and imaging	Fiorella	Iglesias Cardenas	United States	Fiorella Iglesias Cardenas	Poster Session Group D
P350	Cell cycle dynamics of ASCL1 in neuroblastoma cells		Will	Beckman	United Kingdom	Will Beckman	Poster Session Group D